Trial Profile
EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN): ROLE IN POST-PRANDIAL HYPERGLYCEMIA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Pramlintide (Primary) ; Insulin; Insulin aspart; Insulin detemir; Insulin glargine; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Feb 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.